Abiopharma

🔍 Nagendran Sukumar (Executive)

Company: Taysha Gene Therapies, Inc. (TSHA)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Acquired 111,324 shares of Common Stock at $0.6989 per share (Direct)
  Date: 2026-01-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,117,763.00 | transaction_form_type: 4
• Acquired 88,676 shares of Common Stock at $1.71 per share (Direct)
  Date: 2026-01-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,206,439.00 | transaction_form_type: 4
• Sold 200,000 shares of Common Stock at $4.71 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,006,439.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 427,000 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,433,439.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 111,324 shares of Employee Stock Option (right to buy) at $0.6989 per share (Derivative)
  Date: 2026-01-12 | Code: M | Expires: 2033-12-14 | equity_swap_involved: 0 | shares_owned_after: 111,359.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 88,676 shares of Employee Stock Option (right to buy) at $1.71 per share (Derivative)
  Date: 2026-01-12 | Code: M | Expires: 2034-01-02 | equity_swap_involved: 0 | shares_owned_after: 474,941.00 | transaction_form_type: 4 | Footnotes: F5
• Acquired 274,000 shares of Employee Stock Option (right to buy) at $4.86 per share (Derivative)
  Date: 2026-01-12 | Code: A | Expires: 2036-01-12 | equity_swap_involved: 0 | shares_owned_after: 274,000.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
• F4: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
• F5: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
• F6: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.